Alumis Inc. ( (ALMS) ) has shared an update.
On March 4, 2025, Alumis Inc. and ACELYRIN, Inc. announced their commitment to merge in an all-stock transaction, forming a leading clinical-stage biopharma company focused on immune-mediated diseases. The merger is expected to enhance the combined company’s financial position, support a diverse pipeline, and drive significant value for stockholders. The transaction, anticipated to close in the second quarter of 2025, will provide increased resources for developing life-changing medicines and is projected to maximize value for shareholders and patients through a strengthened late-stage portfolio and financial flexibility.
More about Alumis Inc.
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing oral therapies to improve outcomes for patients with immune-mediated diseases. Utilizing a proprietary precision data analytics platform, Alumis is advancing a pipeline of molecules for various immune-mediated conditions. Their leading product candidate, ESK-001, targets plaque psoriasis and systemic lupus erythematosus, while A-005 is aimed at neuroinflammatory and neurodegenerative diseases. ACELYRIN, Inc. is dedicated to developing transformative medicines, with its lead program, lonigutamab, targeting thyroid eye disease.
YTD Price Performance: -43.43%
Average Trading Volume: 197,694
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: $253M
For an in-depth examination of ALMS stock, go to TipRanks’ Stock Analysis page.